Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study - Wikidata - wikimedia - TriplyDB

Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study

Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study

http://www.wikidata.org/entity/Q33810051

about

Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study

http://www.wikidata.org/entity/Q33810051

description

2017 nî lūn-bûn

@nan

2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study

@ast

Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study

@en

type

label

Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study

@ast

Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study

@en

prefLabel

Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study

@ast

Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study

@en

P1433

Q33810051-9F8C2080-FEDF-4945-828E-420081D9CB4E

P1476

Q33810051-0CF7D208-984B-42EF-831C-65F9A6383C04

P2093

Q33810051-1E080D5E-387C-4A74-8DA3-204B7DE38007

Q33810051-26CCE8EC-DD61-4134-AC19-1F96A5E5AF18

Q33810051-2E6A544C-A556-4260-B6D6-69343492E387

Q33810051-74FD55FF-5665-4071-B66F-EFDCCDA24FDE

Q33810051-933A450A-E7E1-449F-8992-DBDB467A08B5

Q33810051-BCD464B4-4E8D-47E5-8426-4756C07B02E9

Q33810051-DECB4114-4533-4C9A-A2F2-A1B1D103657D

Q33810051-E35288C1-87D0-4590-A196-05A9BBBA5CCE

Q33810051-F383C23F-ECAA-46F1-B70F-216C8B339CD8

Q33810051-FB62546C-1756-4CBB-8D5A-600EAB12BE11

P2860

Q33810051-073DD0B9-FC3D-4DB4-BCEB-4D2A94C17213

Q33810051-14B29641-A35D-4B53-961B-30F0B377F2AC

Q33810051-17FCA592-D2F5-4327-9CF2-4B3E65E762BD

Q33810051-196F0AFA-6AFF-46FA-A7F6-D4B61B737A5F

Q33810051-20749E53-F182-4A39-BA11-C04A01961EB3

Q33810051-2B047C53-561D-4587-96CD-E3F6ADFD1084

Q33810051-2C7921EC-5BEB-4C40-9A32-1B4E3E1D8ABA

Q33810051-3E7D7122-5066-4AF1-9B25-34D1AF48369D

Q33810051-3F7B147B-05DF-4513-A064-0C8849B4B5E0

Q33810051-45112D34-CB31-4708-B0EB-2481D6C0E424

P304

Q33810051-FBA5AC9C-6A3F-4817-8E91-AAA7817CAE5D

P31

Q33810051-B055AE53-DBD8-4722-B963-9D84B2008A42

P356

Q33810051-B9C7002A-CA15-41C4-A3D8-7DE1E9AFE089

P433

Q33810051-EE81F196-1D03-4967-B7A8-52DF59F8C2D0

P478

Q33810051-BEA073E3-A12A-4398-84CE-451EA6F48416

P577

Q33810051-6DB6D474-078C-4D10-8705-FEA27D337320

P698

Q33810051-0195D615-4ADD-44C5-959E-01DDABB162CF

P932

Q33810051-36911F51-FF76-4061-8649-EF6E5B7CEFE8

P356

P1433

Brain and Behavior

P1476

Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study

@en

P2093

Alexandra Duffy

http://www.w3.org/2001/XMLSchema#string

John Olichney

http://www.w3.org/2001/XMLSchema#string

Kevin O'Connor

http://www.w3.org/2001/XMLSchema#string

Kiarash Shahlaie

http://www.w3.org/2001/XMLSchema#string

Laura Sperry

http://www.w3.org/2001/XMLSchema#string

Lin Zhang

http://www.w3.org/2001/XMLSchema#string

Mei Yuan

http://www.w3.org/2001/XMLSchema#string

Norika Malhado-Chang

http://www.w3.org/2001/XMLSchema#string

Sarah Farias

http://www.w3.org/2001/XMLSchema#string

Vicki Wheelock

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacology of hallucinations: several mechanisms for one single symptom?

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist

Treatment of psychosis and dementia in Parkinson's disease.

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

Psychiatric syndromes in Parkinson's disease.

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting.

Treatment of psychosis in Parkinson's disease: safety considerations.

Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.

Epidemiology of psychosis in Parkinson's disease.

P304

e00639

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BRB3.639

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28638698

http://www.w3.org/2001/XMLSchema#string

P932

5474696

http://www.w3.org/2001/XMLSchema#string